Opinion|Videos|August 28, 2024
Overview of CAR T-cell Therapy Options in R/R MM
The experts examine the available CAR T-cell therapy options for relapsed/refractory multiple myeloma.
Advertisement
Video content above is prompted by the following:
- What current CAR T- cell therapy options are there for r/r MM? [EX1]
- Resource Link:
CARVYKTI (cilta-cel) HCP website - Reource Link:
ABECMA (ide-cel) HCP website
- Resource Link:
- What are some challenges with CAR T-cell therapy in r/r MM that you’ve experienced in your clinical practice? What are some potential resources and/or strategies to help support logistical challenges or early referral?
- What is the role of bridging therapy prior to CAR T-cell therapy?
- How do you define “bridging therapy”?
- What is the potential role of Selinexor as bridging therapy, and how have you incoporated it in your practice?
Advertisement
Related to this article
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.
Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.
Teclistamab-based induction generated a 91.8% MRD-negative complete response rate with a manageable safety profile in multiple myeloma.
The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.
An analysis of 12 randomized trials validated MRD-negative CR as a surrogate for PFS in earlier-line relapsed/refractory multiple myeloma.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
The OncFive: Top Oncology Articles for the Week of 8/23
3
DAWN-303 Trial Set to Advance INCB161734 in First-Line KRAS G12D–Mutated Metastatic Pancreatic Cancer
4
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
5